Opportunity for QURE Investors to Lead a Major Securities Fraud Case Against uniQure N.V.
On March 23, 2026, the Rosen Law Firm, a prominent player in global investor rights, announced a significant legal opportunity for shareholders of uniQure N.V. (NASDAQ: QURE). If you purchased ordinary shares of uniQure between September 24, 2025, and October 31, 2025, you have until April 13, 2026, to take action as the firm is urging investors to step forward and consider leading a class action lawsuit. This lawsuit addresses serious allegations of securities fraud against the pharmaceutical company.
The call to action emphasizes that those affected by uniQure's alleged misrepresentation can take part in the legal proceedings without having to bear any out-of-pocket expenses. The Rosen Law Firm operates on a contingency fee basis, meaning legal fees are only collected if the case results in a favorable settlement for the plaintiffs. This arrangement opens doors for investors who may typically shy away from potential legal battles due to high costs.
Understanding the Lawsuit
The allegations in the lawsuit stem from claims that uniQure failed to fully disclose crucial regulatory issues regarding its pivotal study related to a key drug candidate aimed at treating Huntington's Disease. Specifically, it's claimed that the design of the study was not wholly approved by the U.S. Food and Drug Administration (FDA). Investors were allegedly misled about the nature of the drug’s trial results, which were touted as successful while downplaying future regulatory hurdles that could delay the submission of its Biologics License Application (BLA).
Upon the revelation of these facts, which contradicted prior statements made by uniQure, the stock's value may have significantly decreased, leading to potential financial losses for investors. The lawsuit seeks compensation for those affected.
Joining the Class Action
To get involved with the uniQure class action, interested parties can follow specific steps outlined by the Rosen Law Firm. Investors are encouraged to visit https://rosenlegal.com/submit-form/?case_id=53025 or contact attorney Phillip Kim directly at 866-767-3653 or via email at [email protected]. This is an opportunity to claim what may rightfully belong to them as investors.
A lead plaintiff is responsible for guiding the litigation process and representing the interests of the class members, so it’s crucial to act promptly. However, it's essential to note that a class has not yet been certified, meaning individuals are not represented unless they choose to engage legal counsel.
Why Choose Rosen Law Firm?
Investors are reminded to carefully select legal representation, particularly during such critical times. Rosen Law Firm stands out for its proven track record in securities class actions, having achieved notable settlements in various cases. The firm occupies a prominent place in the legal landscape, recognized for obtaining substantial recovery for investors over the years. Notably, in 2019 alone, Rosen Law recovered over $438 million for affected parties.
With accolades from various legal publications and recognition for its expertise, the firm commands respect and trust within the investor community. Choosing experienced counsel ensures that investors have competent representation as they navigate the complexities of class action litigation.
Stay Informed
For ongoing updates regarding the uniQure lawsuit and other relevant investor rights issues, you can follow Rosen Law Firm on social media platforms like LinkedIn and Twitter. Timely information can significantly impact decision-making during these proceedings, highlighting the importance of being connected to reliable sources.
As this case unfolds, it reinforces the critical nature of accountability for companies and emphasizes the rights of investors within the financial market. The opportunity to potentially recover losses through this class action highlights the importance of participation from those affected by uniQure’s alleged actions.
Investors are encouraged not to let this opportunity pass and to act swiftly to ensure their voices are heard as part of this significant legal action against uniQure N.V.
The call to action emphasizes that those affected by uniQure's alleged misrepresentation can take part in the legal proceedings without having to bear any out-of-pocket expenses. The Rosen Law Firm operates on a contingency fee basis, meaning legal fees are only collected if the case results in a favorable settlement for the plaintiffs. This arrangement opens doors for investors who may typically shy away from potential legal battles due to high costs.
Understanding the Lawsuit
The allegations in the lawsuit stem from claims that uniQure failed to fully disclose crucial regulatory issues regarding its pivotal study related to a key drug candidate aimed at treating Huntington's Disease. Specifically, it's claimed that the design of the study was not wholly approved by the U.S. Food and Drug Administration (FDA). Investors were allegedly misled about the nature of the drug’s trial results, which were touted as successful while downplaying future regulatory hurdles that could delay the submission of its Biologics License Application (BLA).
Upon the revelation of these facts, which contradicted prior statements made by uniQure, the stock's value may have significantly decreased, leading to potential financial losses for investors. The lawsuit seeks compensation for those affected.
Joining the Class Action
To get involved with the uniQure class action, interested parties can follow specific steps outlined by the Rosen Law Firm. Investors are encouraged to visit https://rosenlegal.com/submit-form/?case_id=53025 or contact attorney Phillip Kim directly at 866-767-3653 or via email at [email protected]. This is an opportunity to claim what may rightfully belong to them as investors.
A lead plaintiff is responsible for guiding the litigation process and representing the interests of the class members, so it’s crucial to act promptly. However, it's essential to note that a class has not yet been certified, meaning individuals are not represented unless they choose to engage legal counsel.
Why Choose Rosen Law Firm?
Investors are reminded to carefully select legal representation, particularly during such critical times. Rosen Law Firm stands out for its proven track record in securities class actions, having achieved notable settlements in various cases. The firm occupies a prominent place in the legal landscape, recognized for obtaining substantial recovery for investors over the years. Notably, in 2019 alone, Rosen Law recovered over $438 million for affected parties.
With accolades from various legal publications and recognition for its expertise, the firm commands respect and trust within the investor community. Choosing experienced counsel ensures that investors have competent representation as they navigate the complexities of class action litigation.
Stay Informed
For ongoing updates regarding the uniQure lawsuit and other relevant investor rights issues, you can follow Rosen Law Firm on social media platforms like LinkedIn and Twitter. Timely information can significantly impact decision-making during these proceedings, highlighting the importance of being connected to reliable sources.
As this case unfolds, it reinforces the critical nature of accountability for companies and emphasizes the rights of investors within the financial market. The opportunity to potentially recover losses through this class action highlights the importance of participation from those affected by uniQure’s alleged actions.
Investors are encouraged not to let this opportunity pass and to act swiftly to ensure their voices are heard as part of this significant legal action against uniQure N.V.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.